Background —The risk factors for ventricular arrhythmias in patients with coronary vasospasm have not been identified. We evaluated QT dispersion in patients with vasospastic angina and its relation to susceptibility to ventricular arrhythmias during myocardial ischemia and reperfusion. Methods and Results —We assessed the corrected QT (QTc) dispersion before induction of coronary artery spasm by intracoronary injection of acetylcholine (baseline) and 30 minutes after administration of isosorbide dinitrate in 50 patients with vasospastic angina and 50 patients with atypical chest pain. The baseline QTc dispersion was significantly greater in patients with vasospastic angina than in patients with atypical chest pain (mean±SD: 69±24 versus 44±19 ms, 95% confidence interval of mean difference [CI]: 16 to 33 ms; P <0.001). QTc dispersion decreased significantly, to 48±15 ms (CI: 15 to 26 ms; P <0.001 versus baseline), after administration of isosorbide dinitrate in patients with vasospastic angina but did not change significantly in patients with atypical chest pain (mean±SD: 41±17 ms, CI: −3 to 9 ms). During the provocation test, 24 of 50 patients with vasospastic angina experienced ventricular arrhythmias. The baseline QTc dispersion was significantly greater in patients with than without ventricular arrhythmias (mean±SD: 77±23 versus 61±19 ms, CI: 4 to 26 ms; P <0.05). Conclusions —Patients with vasospastic angina exhibited an increased baseline QTc dispersion compared with patients with atypical chest pain, which suggests that inhomogeneity of repolarization and susceptibility to ventricular arrhythmias are increased in patients with vasospastic angina, even when asymptomatic. The association between increased QTc dispersion and ventricular arrhythmias during the provocation test suggests that measurement of QT dispersion may help predict which patients with vasospastic angina are at high risk for ventricular arrhythmias during ischemia.
1 March 2003 in Journal of Cardiovascular Electrophysiology
Ibudilast (3‐isobutyryl‐2‐isopropylpyrazolo[1,5‐a]pyridine) is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). It is widely used in Japan for improving prognosis and relieving symptoms in patients suffering from ischemic stroke or bronchial asthma. These clinical applications are based on the properties of ibudilast that inhibit platelet aggregation, improve cerebral blood flow and attenuate allergic reactions. The inhibition of platelet aggregation and vasodilatation by ibudilast may be due to synergistic elevation of intracellular cyclic nucleotides and release of nitric oxide (NO) or prostacyclin from endothelium, rather than direct inhibition of PDE5 or PDE3. Another important property of ibudilast is its antiinflammatory activity possibly associated with potent inhibition of PDE4. Combined with its relaxing effects on bronchial smooth muscle, antiinflammatory actvity of ibudilast could favorably influence pathophysiology of asthma by antagonizing chemical mediators triggering asthmatic attacks. Ibudilast was also reported to significantly attenuate inflammatory cell infiltration in the lumbar spinal cord in an animal model of encephalomyelitis. Future investigations should include effects of ibudilast on inflammatory reactions between endothelium and blood cells, which may initiate the development of atherosclerosis.
Background: Few studies have explored risk stratification of arrhythmic events in patients with ischemic heart diseases according to T-wave alternans (TWA) using modified moving average (MMA) method and heart rate turbulence (HRT). Methods and Results: A retrospective analysis of 63 patients who underwent MMA-based TWA and HRT divided the patients into 3 groups: group-C of 21 controls, group-O of 21 patients with old myocardial infarction (OMI) showing no episodes of sustained ventricular tachyarrhythmia (SVT), and group-V of 21 OMI patients with episodes of SVT who received an implantable cardioverter-defibrillator. Among the 3 groups, positive TWA (≥65 μV) and impaired HRT were observed most frequently in group-V (P<0.05). Using a logistic regression model, TWA yielded an odds ratio of 4.9 (95% confidence interval: 1.2-19.6, P<0.05), which was the only significant covariate for the incidence of life-threatening ventricular arrhythmias during a mean follow-up of 72 months. Conclusions: Patients with OMI showing episodes of SVT have a high risk for cardiac death because of abnormal repolarization and autonomic regulation. The analysis of MMA-based TWA and HRT can be a useful tool for predicting OMI patients at high risk of arrhythmic events. (Circ J 2009; 73: 2223-2228)